Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K9 | P80192 | 5/20 | 0.48 |
| ▸ | MAP3K11 | Q16584 | 5/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 0.48 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
| ▸ | PRKCB | P05771 | 1/20 | 0.41 |
| ▸ | GLI1 | P08151 | 1/20 | 0.41 |
| ▸ | GLI2 | P10070 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PRKACG | P22612 | 1/20 | 0.41 |
| ▸ | PRKACB | P22694 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | PRKCH | P24723 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393376 | 0.84 | CDK1 (0.50) | GPR3PRKD3PRKD1CDK1MAPKAPK2 | |
| SCHEMBL5381430 | 0.77 | TDP2 (0.40) | MAP3K9MAP3K11NTRK1MAP3K10GPR3 | |
| SCHEMBL6652104 | 0.75 | CDK1 (0.58) | NTRK1GPR3PRKD3PRKACAPRKCQ | |
| SCHEMBL1393409 | 0.72 | GPR3 (0.43) | GPR3ALDH1A1ALOX15MAPTTDP1 | |
| Hydrochloric Acid SCHEMBL5240304 | 0.71 | MAP3K9 (0.49) | MAP3K9MAP3K11NTRK1MAP3K10GPR3 | |
| SCHEMBL12013258 | 0.71 | GPR3 (0.52) | GPR3PNMTALDH1A1ALOX15MAPT | |
| SCHEMBL6650273 | 0.70 | PRKD1 (0.38) | GPR3PRKD3PRKD1CDK1MAPKAPK2 | |
| SCHEMBL5387156 | 0.69 | CDK4 (0.49) | MAP3K9MAP3K11GPR3PRKD3PRKCG | |
| SCHEMBL23878721 | 0.69 | HSD17B10 (0.45) | GPR3CDK1MAPKAPK2ALDH1A1ALOX15 | |
| SCHEMBL12228812 | 0.68 | GPR3 (0.43) | MAP3K9MAP3K11GPR3PNMTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735404-B1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | SEAL ROCK THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. | 2021-07-15 | — | — | US | disclosed |
| WO-2020046975-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2019136025-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | SNCA, MAPT, HTT | MAP3K9 166/4885MAP3K11 135/4885NTRK1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.